Apellis Lawsuit Loss Submission Form

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) who purchased common stock between January 28, 2021 and July 28, 2023. The action, which was filed in the United States District Court for the District of Delaware, alleges that the Company violated federal securities laws.

In particular, the Apellis lawsuit alleges that (1) the design of SYFOVRE’s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.

Shareholders have until October 2, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

To learn more and keep informed, complete this form >